21 Best Biotech Stocks to Watch in 2026

What are the best Biotech stocks in 2026?

Here is a list of 21 top biotech stocks to consider for your investment portfolio in February 2026.

1. Vertex Pharmaceuticals (VRTX)

The U.S.-based biopharmaceutical company Vertex maintains its position as the leading cystic fibrosis (CF) treatment provider through its dominant market position which reaches approximately 90% of global sales.

Company Details

• Market Cap: $126.68B 

• Revenue: $12.00B 

• Net Income: $3.95B

2. Regeneron Pharmaceuticals (REGN)

The company Regeneron is a major biopharmaceutical player, known for its biologic therapies in ophthalmology (EYLEA®) and immunology/oncology (e.g., Dupixent® via partner).

Company Details

• Market Cap: $82.20B

• Revenue: $14.34B

• Net Income: $4.50B 

3. Gilead Sciences (GILD)

The company Gilead is a global biopharma leader in HIV, liver disease, and oncology therapies, with a broad product base and scale. It continues to evolve strategy toward higher-growth areas while managing legacy assets.

Company Details

• Market Cap: $193.83B

• Revenue: $29.44B

• Net Income: $8.51B

4. Biogen (BIIB)

The company Biogen is focused on neurology, with key assets in multiple sclerosis (MS) and Alzheimer’s disease, and is undergoing portfolio transformation toward rare diseases and immunology.

Company Details

• Market Cap: $28.96B 

• Revenue: $9.89B

• Net Income: $1.29B

5. Alnylam Pharmaceuticals, Inc. (ALNY)

The company Alnylam leads the field of RNA interference (RNAi) therapeutics by providing first-in-class treatments for rare genetic diseases. The platform of the company continues to expand the possibilities of gene silencing technologies.

Company Details

• Market Cap: $41.46B

• Revenue: $3.71B 

• Net Income: $313.75M

6. Argenx (ARGX)

Argenx develops antibody-based treatments for autoimmune diseases through its proprietary FcRn platform. Its lead product, VYVGART®, continues to expand globally across multiple indications.

Company Details

• Market Cap: $51.05B 

• Revenue: $3.68B 

• Net Income: $1.53B

7. BioMarin Pharmaceutical (BMRN)

BioMarin focuses on rare genetic disorders and enzyme replacement therapies. Its new gene therapy Roctavian® for hemophilia A marks a major commercial milestone.

Company Details

• Market Cap: $11.57B

• Revenue: $3.09B

• Net Income: $520.42M

8. Incyte Corporation (INCY)

Incyte is an oncology and immunology company best known for Jakafi® and its expanding dermatology portfolio led by Opzelura®.

Company Details

• Market Cap: $20.18B

• Revenue: $5.14B

• Net Income: $1.29B

9. CRISPR Therapeutics (CRSP)

CRISPR Therapeutics pioneers gene-editing technologies and co-developed Casgevy®, the first FDA-approved CRISPR therapy for sickle-cell disease and β-thalassemia.

Company Details

• Market Cap: $5.11B 

• Revenue: $3.51M

• Net Income: $-581.60M

10. Beam Therapeutics (BEAM)

Beam Therapeutics develops next-generation gene-editing therapies using precision base editing technology designed to correct genetic mutations without cutting DNA. The company’s collaborations with Pfizer and Verve Therapeutics enhance its clinical reach.

Company Details

• Market Cap: $2.77B 

• Revenue: $55.70M

• Net Income: $-414.64M

11. Intellia Therapeutics (NTLA)

Intellia Therapeutics focuses on in-vivo and ex-vivo CRISPR-based gene editing. It is among the first to demonstrate systemic in-vivo editing in humans with encouraging early clinical data in transthyretin amyloidosis.

Company Details

• Market Cap: $1.39B 

• Revenue: $57.53M

• Net Income: $-445.81M

12. Moderna (MRNA)

Moderna is a global biotechnology leader pioneering mRNA-based vaccines and therapeutics. Following its COVID-19 success, the company is expanding into oncology, RSV, and rare-disease applications.

Company Details

• Market Cap: $16.78B

• Revenue: $1.94B

• Net Income: $-2.82B

13. Genmab A/S (GMAB.CO)

Genmab operates as a Danish biotech organization which focuses on developing antibody-based cancer therapies through innovative approaches.

Company Details

• Market Cap: $115.87B

• Revenue: $24.48B

• Net Income: $10.08B

14. CSL Limited (CSL.AX)

CSL operates as a major Australian biopharmaceutical organization which focuses on plasma therapies alongside vaccines and rare disease treatments.

Company Details

• Market Cap: $72.31B 

• Revenue: $23.10B

• Net Income: $2.09B

15. Novo Nordisk (NVO)

The company Novo Nordisk is a global leader in diabetes and obesity care, driven by its semaglutide-based therapies (like Wegovy® and Ozempic®). It continues to expand manufacturing capacity and global reach.

Company Details

• Market Cap: $219.20B

• Revenue: $48.59B

• Net Income: $16.10B

16. Lonza Group (LZAGY)

Lonza Group operates as a major contract development and manufacturing organization (CDMO) in biologics, cell & gene therapies, and small molecules, servicing global pharma & biotech clients.

Company Details

• Market Cap: $45.48B

• Revenue: $8.24B

• Net Income: $1.20B 

17. Karuna Therapeutics (KRTX)

Karuna is a clinical-stage biopharmaceutical company developing therapies for psychiatric and neurologic disorders (notably its lead candidate KarXT).

Company Details

• Market Cap: $2.82B

• Revenue: $7.48B

• Net Income: $295.00M

18. Madrigal Pharmaceuticals (MDGL)

Madrigal develops therapies for liver-metabolic diseases (notably NASH/MAFLD) and has recently launched its first commercial product following FDA approval, positioning it for rapid growth.

Company Details

• Market Cap: $10.55B 

• Revenue: $740.64M

• Net Income: $-289.13M

19. Viking Therapeutics (VKTX)

Viking is a clinical-stage biotech developing metabolic and endocrine drugs, including oral candidates in obesity and liver disease.

Company Details

• Market Cap: $3.43B

• Revenue: n/a

• Net Income: $-359.64M

20. Summit Therapeutics Inc. (SMMT)

Summit Therapeutics operates as a U.S.based biopharmaceutical company which specializes in precision oncology through its lead asset Ivonescimab that targets TP53-mutant and other challenging-to-treat cancers. 

Company Details

• Market Cap: $11.64B

• Revenue: n/a

• Net Income: $-921.62M

21. Structure Therapeutics (GPCR)

Structure Therapeutics is a clinical-stage biotech developing novel oral small-molecule therapies targeting G-protein coupled receptors (GPCRs) for metabolic and pulmonary diseases

Company Details

• Market Cap: $4.96B

• Revenue: n/a

• Net Income: $-210.69M

How These Biotech Stocks Were Selected

These biotech stocks were selected based on their exposure to breakthrough areas such as gene editing, personalized medicine, and mRNA technologies. We focused on companies with strong late-stage clinical pipelines, strategic partnerships, and clear commercialization pathways. Financial strength, cash runway, and innovation depth were key factors in the screening process. The selection aims to capture firms positioned to benefit from new product launches and expanding market adoption through 2026 and beyond.

Risks Before Investing in Biotech Stocks

• Clinical trial failures or regulatory rejections can significantly impact company valuations and growth prospects.

• High research and development costs with uncertain outcomes can create funding and profitability challenges.

• Smaller or early-stage biotech firms tend to have higher volatility and financial risk compared to established biopharma companies.

• Overconcentration in a single therapy area or company increases exposure to scientific, regulatory, and market uncertainties.

Conclusion: Balancing Innovation & Caution

The 21 biotech stocks for 2026 represent both established leaders and high-growth innovators, which makes them exciting investment opportunities. The high potential rewards come with significant risks, which require investors to diversify their portfolios and conduct continuous research.

These biotech stock investment choices offer healthcare investors a solid foundation to access future healthcare opportunities. If you are looking to expand further, feel free to also explore areas like Pharma stocks and Healthcare stocks to build a well-rounded portfolio.